Cargando…
SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting
BACKGROUND: Delayed-released dimethyl fumarate (DMF) is an oral disease-modifying therapy (DMT) approved for treating patients with multiple sclerosis (MS). This post-marketing study aimed at collecting real-world data on the safety, effectiveness, and tolerability of DMF in patients with relapsing...
Autores principales: | Zecca, Chiara, Czaplinski, Adam, Henny, Christophe, Petrini, Liliane, Beeler, Andreas, Gobbi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772546/ https://www.ncbi.nlm.nih.gov/pubmed/33385094 http://dx.doi.org/10.1016/j.heliyon.2020.e05819 |
Ejemplares similares
-
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019) -
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015) -
Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
por: Zecca, Chiara, et al.
Publicado: (2019) -
Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018) -
A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure
por: Ramseier, Simon P, et al.
Publicado: (2015)